145 related articles for article (PubMed ID: 24013519)
41. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
42. Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic purpura.
Marmont AM
Bone Marrow Transplant; 1999 Jun; 23(12):1215-6. PubMed ID: 10414905
[No Abstract] [Full Text] [Related]
43. Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.
Shimizu H; Saitoh T; Hatsumi N; Takada S; Handa H; Jimbo T; Sakura T; Miyawaki S; Nojima Y
Leuk Res; 2013 Nov; 37(11):1477-81. PubMed ID: 24054717
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
45. Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia.
Nakaseko C; Sakaida E; Ohwada C; Ozawa S; Takeuchi M; Shimizu N; Cho R; Yokota A; Saito Y; Nishimura M
Ann Hematol; 2007 Jan; 86(1):67-9. PubMed ID: 17021838
[No Abstract] [Full Text] [Related]
46. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
47. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden.
Zhang WP; Yang D; Song XM; Ni X; Chen J; Chen L; Yang JM; Zhou H; Cheng H; Liu BH; Li HM; Wang JM
Biol Blood Marrow Transplant; 2013 Apr; 19(4):653-60. PubMed ID: 23353118
[TBL] [Abstract][Full Text] [Related]
48. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.
Bartsch K; Al-Ali H; Reinhardt A; Franke C; Hudecek M; Kamprad M; Tschiedel S; Cross M; Niederwieser D; Gentilini C
Transplantation; 2009 Jan; 87(2):217-21. PubMed ID: 19155975
[TBL] [Abstract][Full Text] [Related]
49. Severe intestinal graft versus host disease after donor lymphocyte infusion; response to extracorporeal photochemotherapy.
Vural F; Donmez A; Doganavşargil B; Cagýrgan S; Alper H; Tombuloglu M
Transfus Apher Sci; 2005 Oct; 33(2):129-33. PubMed ID: 16150645
[TBL] [Abstract][Full Text] [Related]
50. Natural History, Pathogenesis, and Treatment of Evans Syndrome in Children.
Mantadakis E; Farmaki E
J Pediatr Hematol Oncol; 2017 Aug; 39(6):413-419. PubMed ID: 28654461
[TBL] [Abstract][Full Text] [Related]
51. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
52. Autoimmune polyglandular syndrome type III after haploidentical hematopoietic stem cell transplantation in a child with acute myeloid leukemia.
Kleinschmidt K; Martoni A; Masetti R; Cassio A; Prete A; Pession A
Pediatr Blood Cancer; 2012 Aug; 59(2):341. PubMed ID: 21994118
[No Abstract] [Full Text] [Related]
53. Comparison of reduced intensity and myeloablative conditioning regimens for stem cell transplantation in patients with malignancies: a meta-analysis.
Shi-Xia X; Hai-Qin X; Xian-Hua T; Bo F; Xiang-Feng T
Clin Transplant; 2011; 25(2):E187-98. PubMed ID: 21092011
[TBL] [Abstract][Full Text] [Related]
54. T-cell lymphoproliferative disorder following a full haplotype-mismatched haematopoietic stem cell transplant in a patient with acute myeloid leukaemia.
Rhee CK; Rhee JH; Kim HJ; Choi SM; Kim YJ; Kim DW; Lee JW; Min WS; Shin WS; Kim CC; Ahn KJ
Bone Marrow Transplant; 2005 Sep; 36(5):461-3. PubMed ID: 15968275
[No Abstract] [Full Text] [Related]
55. Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient.
Endo T; Nakao S; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Koike T
Ann Hematol; 2004 Feb; 83(2):114-6. PubMed ID: 14513283
[TBL] [Abstract][Full Text] [Related]
56. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
57. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
Pusic I; Pavletic SZ; Kessinger A; Tarantolo SR; Bishop MR
Bone Marrow Transplant; 2002 Apr; 29(8):709-10. PubMed ID: 12180118
[TBL] [Abstract][Full Text] [Related]
58. Improved myeloablative conditioning regimen for allogeneic stem cell transplantation in adult patients with chronic myelomonocytic leukaemia.
Zhang T; Liu X; Fei H; Zhang L; Ma R; Shen Y; Pang A; Yang D; Chen X; Zhang R; Wei J; He Y; Jiang E; Han M; Feng S
Br J Haematol; 2023 Jan; 200(2):256-260. PubMed ID: 36367209
[No Abstract] [Full Text] [Related]
59. New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Cluzeau T; De Matteis M; Mounier N; Mannone L; Gratecos N; Ticchioni M; Thyss A; Raynaud S; Cassuto JP; Sirvent A
Am J Hematol; 2011 Jul; 86(7):619-21. PubMed ID: 21509800
[No Abstract] [Full Text] [Related]
60. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation.
Ayuk F; Bussmann L; Zabelina T; Veit R; Alchalby H; Wolschke C; Lellek H; Bacher U; Zander AR; Kröger N
Ann Hematol; 2014 May; 93(5):855-61. PubMed ID: 24248672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
